Science Corporation Secures $230 Million in Oversubscribed Series C Funding to Advance BCI Commercialization

Recently, according to foreign media reports, Science Corporation announced that its oversubscribed$230 Million Series C FinancingHas ended.

Image Source: Latest Medical Device News on MassDevice

According to Science Corporation, participants in this round of financing include Lightspeed Venture Partners, Khosla Ventures, Y Combinator, IQT, and Quiet Capital, among others. The funds will be used to accelerate the commercialization process of its brain-computer interface technology. Currently, the companyHas obtained a total accumulated financing amount reaching approximately 490 million US dollars。

It is reported that Science Corporation, headquartered in Alameda, California, was founded in 2021. The company, led by Max Hodak, a co-founder of Neuralink, is currently...Advance the Clinical Trials of the Prima Retinal Implant。

It is worth mentioning that Science owns the Prima retinal implant technology developed by Pixium Vision. The Prima system serves as a photovoltaic substitute for photoreceptor cells.Granted Breakthrough Device Designation by the U.S. Food and Drug Administration, which allows for the simultaneous use of central prosthetic vision and peripheral natural vision.

Moreover, Prima technology can restore vision by directly stimulating the retina when rod and cone cells are lost. The system includes a small photodynamic implant placed under the retina, and a pair of specially designed glasses. These glasses are equipped with a camera and an infrared projector, which send light signals to the implant, providing it with power and data.

Currently, Science has submitted the marketing application for Prima to the U.S. and European regulatory authorities in June. In October 2025, the company reported positive outcomes from users of the Prima implant.

According to foreign media reports, Science CorporationExpected to become the first brain-computer interface company with a vision restoration product launched for commercial sale, planning to release its product in Europe this year.The company stated that this round of C-series financing was driven by strong investor demand, given the multiple milestones the company is expected to achieve in the future.

The company also plans to use the funds to supportThe Development of Its Biohybrid Neural Interface Technology and Vessel Perfusion SystemIts biohybrid architecture is designed to connect with the brain while avoiding the potential damage and limitations of inserting wires into the brain. The Vessel platform represents a reimagining of how extracorporeal membrane oxygenation works.

In addition, Science Corporation has expanded its PRIMA clinical trial program to evaluate its efficacy in other retinal diseases. These include Stargardt disease and retinitis pigmentosa, both of which can lead to retinal vision loss in young people due to genetic factors.

At the same time, the company is waiting for CE mark certification in Europe and FDA approval in the United States.Its product is expected to become the first vision-restoration brain-computer interface to hit the market.Meanwhile, Neuralink, a brain-computer interface company previously founded by Hodak, is also developing a vision-restoring implant.

It is worth mentioning that the BCI track is currently very popular. In addition to foreign companies such as Precision, Neuralink, and Synchron accelerating their layout, the BCI track in China is also in full swing.

In terms of policy direction, in recent years, multiple policies in China have been continuously promoting the development of the brain-computer interface industry. Nationally"The Fifteenth Five-Year Plan"Also lists brain-computer interface as one of the six future industries. Among the policies in various regions, Shanghai's "Action Plan for the Cultivation of the Brain-Computer Interface Future Industry (2025-2030)" explicitly proposesBy 2027, drive more than 5 invasive and semi-invasive products to complete clinical trials.

With policy support, multiple medical device companies in China have already made moves in this area, such as BrainLink, NeuraLink Technology, and Zhiran Medical. BrainLink's core product, NEO, is a semi-invasive device, while NeuraLink Technology focuses on the non-invasive track. Both companies launched their IPOs in February, aiming to become China’s first brain-computer interface stock.

Zhiran Medical has recently completed a Series A+ round of financing, having completed two rounds of financing within half a year, with an amount as high as 600 million yuan. In 2025, Zhiran Medical completed the first clinical implantation in China of an invasive brain-computer interface product with over a hundred channels. In 2026, it is expected to initiate large-scale registered clinical trials for this over-a-hundred-channel invasive brain-computer interface product.